COPYRIGHT © DIGITAL JOURNAL INC. Sitemaps: XML / News. Digital Journal is not responsible for the content of external sites. Read more about our external linking
During the forecast period 2023 to 2033, the Gastrointestinal stromal tumor (GIST) therapeutics market is expected to grow at a value of 6% CAGR, according to Future Market Insights. By the year 2033, the global market for Gastrointestinal stromal tumor (GIST) therapeutics is expected to rise up to a market valuation of US$ 1593 Million. An aging population is a major driver for the market growth of gastrointestinal stromal tumor (GIST) therapeutics market.
Advances in healthcare and a growing number of treatment options for various illnesses, including cancer, have led to a higher life expectancy worldwide. Increased awareness of life-threatening conditions is also contributing to this trend. China, India, and Brazil are some of the fastest-growing nations in terms of their elderly populations and advances in healthcare are expected to further contribute to this growth. As a result, the market for GIST therapeutics is expected to grow during the forecast period.
Request Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16670
GIST therapeutics is expected to continue to grow in the coming years, driven by advances in research and development, increasing demand for effective treatments, and an aging patient population. Furthermore, North America and Asia Pacific are the two major regions contributing to the growth of the GIST therapeutics market owing to the increase in geriatric population across the regions.
Key Takeaways from the Market Study
“Technological advancements along with development of different therapeutics treatments is creating lucrative opportunities for GIST therapeutics market.” states an FMI analyst
Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-16670
Competitive Landscape
Key players in the gastrointestinal stromal tumor (GIST) therapeutics are Arog Pharmaceuticals, Taiho Pharmaceutical, Turning Point Therapeutics, Inc, Cogent Biosciences, Inc, Plexxikon Inc, Theseus Pharmaceuticals, Exelixis, Inc, Ipse, Bristol-Myers Squibb and Takeda
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Gastrointestinal stromal tumor (GIST) therapeutics market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of Drug Type (Imatinib, Ripretinib, Crenolanib, Regorafenib, Avapritinib, Sunitinib, Entrectinib, Larotrectinib) Therapy (Targeted therapy, Chemotherapy, Radiation therapy) End User (Hospitals, Clinics, Specialized Cancer Treatment Centres) & Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, MEA)
Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16670
Key Segments Profiled in the Gastrointestinal Stromal Tumor (GIST) Therapeutics Industry Survey
Drug Type:
Therapy:
End User:
Explore FMI’s Extensive ongoing Coverage on Healthcare Domain:
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs
The post Gastrointestinal Stromal Tumor (GIST) Therapeutics Market to Register 6% CAGR in 2023 to 2033 | FMI Study appeared first on Future Market Insights.